US20120045846A1 - SYSTEM AND METHOD FOR pH FORMULATIONS - Google Patents

SYSTEM AND METHOD FOR pH FORMULATIONS Download PDF

Info

Publication number
US20120045846A1
US20120045846A1 US13/214,353 US201113214353A US2012045846A1 US 20120045846 A1 US20120045846 A1 US 20120045846A1 US 201113214353 A US201113214353 A US 201113214353A US 2012045846 A1 US2012045846 A1 US 2012045846A1
Authority
US
United States
Prior art keywords
solution
chemical denaturant
denaturant
buffer
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/214,353
Inventor
Richard Brown
Burleigh Hutchins
Ernesto Freire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unchained Labs Inc
Original Assignee
Avia Biosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avia Biosystems LLC filed Critical Avia Biosystems LLC
Priority to US13/214,353 priority Critical patent/US20120045846A1/en
Priority to PCT/US2011/048799 priority patent/WO2012027361A2/en
Publication of US20120045846A1 publication Critical patent/US20120045846A1/en
Assigned to AVIA BIOSYSTEMS, LLC reassignment AVIA BIOSYSTEMS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUTCHINS, LORRAINE, BROWN, RICHARD, FREIRE, ERNESTO
Priority to US14/709,666 priority patent/US9606061B2/en
Assigned to UNCHAINED LABS INC. reassignment UNCHAINED LABS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AVIA BIOSYSTEMS, LLC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1065Multiple transfer devices
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6486Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/38Diluting, dispersing or mixing samples
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/10Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
    • G01N35/1065Multiple transfer devices
    • G01N35/1072Multiple transfer devices with provision for selective pipetting of individual channels

Definitions

  • Protein therapeutics is the fastest growing segment of the biotechnology and pharmaceutical industry. Protein therapeutics includes monoclonal antibodies, recombinant proteins, chimeric proteins and other protein receptor constructs. This segment is expected to reach over $70 billion in sales by 2011.
  • Temperature is one of the most widely used physical denaturants. In this scenario, a protein is subjected to increasing temperature and the corresponding changes in its structure are recorded.
  • One of the disadvantages of temperature denaturation is that proteins typically denature at temperatures at or above 60° C. However, in most instances, the temperatures of interest are physiological (about 37° C.), room (about 25° C.) and storage (4° C.). Thus, results from temperature-based denaturation tests must be extrapolated by more than 25° C. to understand the effects at the temperatures of interest.
  • most proteins used as biologics undergo irreversible temperature denaturation, which precludes a meaningful calculation of thermodynamic stability at the temperatures of interest. Also, a formulation that elicits a higher denaturation temperature does not necessarily result in a more stable protein at room temperature.
  • a second way to measure protein stability is through the use of chemical denaturants, such as urea or guanidine hydrochloride. This method permits measurements to be done at any desired temperature.
  • the structural stability of a protein is determined by its Gibbs energy of stability, ⁇ G. This value, ⁇ G, is a function of temperature, chemical denaturants and other physical and chemical variables.
  • ⁇ G Gibbs energy of stability
  • K f is the rate of the folding reaction
  • K u is the rate of the unfolding reaction
  • K can be defined as the ratio of the unfolding rate to the folding rate
  • K K u K f .
  • the Gibbs energy can be expressed in terms of K, as
  • K is the gas constant
  • T is the temperature
  • ln(K) is the natural log of K.
  • ⁇ G 0 is the intrinsic Gibbs energy
  • [denaturant] is the concentration of denaturant
  • m is the multiplier, which is unique for a particular protein.
  • This equation can be used to allow calculation of a denaturation curve.
  • certain measurable characteristics of the protein also change.
  • One such characteristic is the fluorescence of the protein.
  • fluorescence emission Intrinsic or extrinsic
  • the disclosure is not limited to this technique.
  • FIG. 1 shows a typical urea denaturation curve for an antibody.
  • the y, or vertical, axis is a measure of the intrinsic fluorescence of the protein.
  • the fluorescence of different dyes, usually known as protein probes, can also be used.
  • the horizontal, or x, axis is the concentration of urea in solution with the protein. As can be seen, at a certain point, between 3M and 4M urea, the fluorescence of the protein changes dramatically, indicating that it has denatured.
  • a solution containing the protein and any excipients is prepared. A sample of this solution is then subjected to fluorescent light and the emission is recorded. This is the baseline fluorescence with no chemical denaturant.
  • an amount of urea is then added to the remainder of the solution, and the light test is repeated on a portion of this modified solution. An additional amount of urea is then added to the remainder of the solution and a third light test is performed. This process is repeated for the number of desired samples. The amount of urea added each time is a function of the desired granularity of the test, and the range of urea molarities to be included.
  • a plurality of solutions each with the protein, any excipients, and the proper amount of urea, is individually prepared.
  • Each of these prepared solutions is then light tested to determine its fluorescence. While this method removes the cumulative errors associated with the previous method, it is extremely time consuming, especially for a large number of samples.
  • the resulting denaturation graph shows the stability of a particular combination of buffer, ligand and excipient conditions in the presence of a chemical denaturant. More stable combinations have a similarly shaped graph, shifted to the right. Conversely, less stable combinations have a graph shifted to the left. The goal of this testing is to find a combination with the maximum stability in the presence of the chemical denaturant. This combination can then be used as the storage formulation for the protein as it is stored and shipped.
  • pH one important parameter that affects protein stability is pH.
  • a system and method for automatically creating a buffer solution having a desired pH value is disclosed.
  • the method uses two known buffer solutions, each with predetermined or known pH values, and determines a mathematical relationship which defines the amount of each known buffer solution needed to create the buffer solution with the desired pH. This method can then be used to create one or more denaturation graphs, which demonstrate the stability of a protein at a given pH level.
  • FIG. 1 is a denaturation graph of the prior art
  • FIG. 2 is a flowchart illustrating a process to generate a denaturation graph with a desired salt concentration
  • FIG. 3 is a graph showing the relationship between Fraction Basic and pH for a particular buffer
  • FIG. 4A is the inverse of FIG. 3 ;
  • FIG. 4B is a best fit fourth order equation
  • FIG. 4C is a best fit fifth order equation
  • FIG. 5 is a flowchart illustrating a process to determine the non-linear best fit relationship between pH and Fraction Basic for a particular buffer
  • FIG. 6 is a flowchart illustrating a process to generate a denaturation graph with a desired pH
  • FIG. 7 is a flowchart illustrating a process to create a library of predetermined best fit equations for a plurality of buffers.
  • FIG. 1 shows a typical denaturation graph, used to determine the stability of a protein in the presence of a chemical denaturant.
  • This graph shows the stability of the protein for a particular combination of buffer, ligand and excipients conditions. However, it is often useful to view a plurality of these graphs to understand how changes in the buffer, ligand or excipients affects the stability of the protein.
  • a compound such as a salt, pH, excipients, or ligands may affect the stability of the protein.
  • a compound such as a salt, pH, excipients, or ligands
  • it may be of interest to measure the effects of different concentrations of salt in combination with a particular buffer and ligand. To do this, one may create four different formulations:
  • Formulations 1 and 3 contain a minimum amount of denaturant, which may be greater than 0, while Formulations 2 and 4 contain a maximum amount of denaturant.
  • formulations 3 and 4 can be used to create a second denaturation graph, showing the stability of a solution with a maximum amount of salt with varying amounts of chemical denaturant.
  • a set of other graphs can also be created, each of which has a salt concentration between the minimum and maximum values.
  • the particular number of graphs within the set is not particularly limited, and can be predetermined or arbitrary.
  • a denaturation graph showing the effect of chemical denaturant, with a salt concentration that is the average of the minimum and maximum values may be created.
  • a new formulation is created by mixing Formulation 1 and Formulation 3 in equal amounts. This new formulation has a salt concentration exactly halfway between the minimum and maximum values, with no chemical denaturant.
  • a second new formulation is created by mixing equal amounts of Formulation 2 and Formulation 4. This new formulation has a salt concentration exactly halfway between the minimum and maximum values, with a maximum amount of chemical denaturant.
  • the denaturant graph for this salt concentration is then created as described above.
  • FIG. 2 shows a flowchart showing this sequence.
  • step 100 the four formulations, labeled F 1 through F 4 , are prepared. These four formulations represent the four corners of the testing.
  • step 110 a fifth formulation, which has the desired amount of salt and no chemical denaturant, is prepared, using the equation shown. This equation assumes a linear relationship and is used to create any desired concentration between the minimum salt concentration and the maximum salt concentration.
  • step 120 a sixth formulation, which has the desired amount of salt and the maximum amount of chemical denaturant is prepared, using the equation shown.
  • the fifth and sixth concentrations may each be prepared in a separate well or vessel, so as to be available for future use.
  • the fifth and sixth formulations need not be independently created. Rather, the formulations F 1 , F 2 , F 3 and F 4 may be combined in the specific ratios described by these equations in a single well or vessel, without the intermediate formulations F 5 , F 6 being prepared in a separate vessel.
  • the terms “fifth formulation” and “sixth formulation” are used to express the ratios of F 1 and F 3 , and F 2 and F 4 , respectively, even in the scenario where such formulations may not exist in an isolated vessel.
  • a denaturation graph can be prepared. For an eleven point graph, the F 5 and F 6 formulations may be combined as shown in Table 1 below.
  • each of these points is prepared and then subjected to testing, where the observable property is measured.
  • this testing includes the measurement of the fluorescence emission of the protein itself (intrinsic) or a fluorescence probe that is sensitive to protein denaturation after being excited with a light of a wavelength that is absorbed by the protein or fluorescence probe.
  • the fluorescence of each data point is measured and recorded.
  • the fluorescence is then plotted as a function of the molarity of the chemical denaturant.
  • the result of this process is a denaturation graph.
  • the process shown in FIG. 2 can be repeated for an arbitrary number of salt concentrations.
  • Certain elements, such as salt, can be mixed according to linear models, using the equations shown in steps 110 and 120 of FIG. 2 .
  • an acidic solution having a pH of 4, is created.
  • the solution may contain L-histidine and is made acidic through the introduction of one or more acids, such as succinic acid and/or phosphoric acid. If necessary, the pH can be increased through the introduction of NaOH.
  • a basic solution, having a pH of 9, is also created using L-histidine. In this case, Na 2 HPO 4 is used to make the solution basic. If necessary, the pH can be further increased through the introduction of NaOH.
  • these two solutions are mixed in a plurality of combinations, and the pH of each resulting mixture is measured.
  • FIG. 3 shows the actual measured pH for these solutions.
  • the x, or horizontal, axis is the fraction of the resulting mixture which is the base, also referred to as Fraction Basic (F B ), expressed as
  • V B is the volume of basic solution and V A is the volume of acidic solution.
  • the y, or vertical, axis represents the pH of the mixture.
  • the points on the graph represent actual measured pH values, while broken line 150 is used to show a theoretical linear relationship between x and y from the pH 4 solution to the pH 9 solution.
  • a linear relationship such as that used in FIG. 2 , is not an accurate representation of the pH relationship.
  • the method and equations described in conjunction with FIG. 2 will not produce accurate results.
  • FIG. 3 shows the pH of mixtures of two solutions. Different curves may be obtained if L-histidine is replaced with a different protein stabilizing inducing ligand.
  • FIG. 4A shows the graph of Fraction Basic (F B ) as a function of pH. This is obtained by simply reversing the coordinates of each point on the graph shown in FIG. 3 .
  • Line 160 again is drawn to show a theoretical linear relationship between Fraction Basic (F B ) and pH, from the pH 4 solution to the pH 9 solution.
  • a best fit cubic equation is generated. For example, in the example shown in FIGS. 3 and 4A , the best fit cubic equation is given by:
  • FIG. 4B shows a best fit fourth order equation, given by the formula:
  • FIG. 4C shows a best fit fifth order equation, given by the formula:
  • FIG. 5 represents a simplified flowchart of this operation.
  • the buffer is prepared in two solutions, one acidic having a first pH, and one basic, having a second, higher pH.
  • the two pH values can be any values, such as 3 and 9, or other ranges.
  • a plurality of formulations is prepared, each with a unique Fraction Basic (F B ).
  • F B Fraction Basic
  • formulations having twenty or more unique F B values are created.
  • Each of these formulations is then tested to determine its pH, as shown in step 220 .
  • the results of this test are plotted, as shown in step 230 .
  • the inverse function which shows F B as a function of pH, is then created, as shown in step 240 .
  • step 240 can be generated directly from the data generated in step 220 .
  • a computer tool or other method, may be used to determine the best non-linear best fit mathematical relationship between pH and F B for this buffer, as shown in step 250 .
  • a cubic equation is generated, although other order polynomials may also be used.
  • FIG. 6 shows a modified version of the flowchart of FIG. 2 , which can be used to generate denaturation graphs for a plurality of pH values.
  • this method allows the creation of a buffer of any desired pH simply by mixing two solutions of different pH values in appropriate proportions, as determined by a non-linear mathematical relationship, such as a cubic equation.
  • the fifth and sixth concentrations F 5 , F 6 respectively, can each be prepared in a separate well or vessel, so as to be available for future use. However, in other embodiments, the fifth and sixth formulations may not be independently created.
  • the formulations F 1 , F 2 , F 3 and F 4 may be combined in the specific ratios described by these equations in a single well or vessel, without the intermediate formulations F 5 , F 6 being prepared in a separate vessel.
  • the terms “fifth formulation” and “sixth formulation” are used to express the ratios of F 1 and F 3 , and F 2 and F 4 , respectively, even in the scenario where such formulations may not exist in an isolated vessel. This method is ideally suited for automatic generation of buffer solutions of specified pH values
  • FIG. 7 shows a method that is used to create a library of buffers, which can then be used to create a plurality of denaturation graphs for any protein.
  • a first buffer is prepared in acid and base solutions, as shown in step 300 .
  • formulations having various Fraction Basic values are prepared, as shown in step 310 .
  • Each formulation is pH test (step 320 ) and based on this, the non-linear best fit mathematical relationship is determined for this particular ligand, as shown in step 340 .
  • This equation is then saved, and associated with the particular buffer, such as in a database or other computer storage medium, as shown in step 340 .
  • a different buffer is selected (step 350 ) and this process is repeated. This process can be performed for as many buffers as desired.
  • the generation of a table or database of buffers, and corresponding non-linear best fit equations can be used to determine the best buffer to use with a particular protein.
  • a particular protein has been identified as suitable for a pharmaceutical purpose, it may be advantageous to determine the pH and buffer in which the protein is most stable.
  • the operator may select a first buffer, which has been previously characterized such that a pre-determined non-linear best fit mathematical relationship exists.
  • the operator may then select the desired range of pH values that are desired to be tested, as well as the division or step size.
  • a set of denaturation graphs is generated for the selected buffer, where each graph represents a specific pH value within the range requested by the operator.
  • the operator may select a second buffer, which has been previously characterized such that a pre-determined non-linear best fit mathematical relationship exists.
  • the procedure detailed above is then repeated for this second buffer. This process can be repeated for as many buffers as desired.
  • the processes described herein may be automated.
  • an apparatus having a controller with a processing unit and a storage element is used.
  • the storage element may be RAM, DRAM, ROM, Flash ROM, EEROM, magnetic media, or any other medium suitable to hold computer readable data and instructions.
  • the instructions may be those necessary to execute the flowchart of FIG. 2 , FIG. 5 or FIG. 6 .
  • the processing unit may be a dedicated microcontroller, a personal computer or any other suitable computing device.
  • the apparatus has a pump or siphon system, which allows cannulas to extract liquid from a first well (F 1 ), a second well (F 2 ), a third well (F 3 ) and a fourth well (F 4 ) in exact quantities and mix these liquids together, preferably in another well.
  • the apparatus also includes one or more actuators, which can move the cannulas from one position to another, so as to draw fluid from a first well and expel the fluid into a second well.
  • the operator may enter the identity of the buffer that is desired.
  • the equipment, in its storage element may have a mapping which correlates the selected buffer with the non-linear equation to be used. The operator then enters the pH minimum, pH maximum and pH step size. In another embodiment, the operator enters the coefficients of the non-linear best fit equation.
  • the generation of the non-linear mathematical relationship is generated automatically.
  • the controller may be in communication with a pH indicator. This is so that after using the above described equipment to create formulations with various Fraction Basic values, the pH indicator may provide pH information to the controller, as shown in steps 230 and 240 .
  • the controller may also have a software application that creates a non-linear best fit mathematical relationship based on the Fraction Basic values and the measured pH values. Using the resulting best fit mathematical relationship, a formulation having any desired pH can be created.
  • the controller executed a series of instructions or steps.
  • the coefficients of the non-linear best fit equation are selected, which allows the controller to determine Fraction Basic for a given pH.
  • the pH to be tested is determined. For the first test, this is equal to the pH minimum entered by the operator.
  • the controller For each pH, the controller, using the flowchart of FIG. 6 , creates a denaturation curve.
  • This data can be output, such as on a display device or printer.
  • this graph is stored in the storage element of the apparatus.
  • the new pH to be tested is equal to pH min+pH step size*(test number ⁇ 1). In other words, the new pH to be tested is equal to the pH that was previously tested+pH step size.
  • a new Fraction Basic is determined, and the process of FIG. 6 is repeated. This process is repeated until the pH to be tested is greater than the pH maximum entered by the operator. At this point, the pH testing for the selected buffer has been completed.
  • the operator may then enter a different buffer to be tested and enter the required parameters to the apparatus and repeat the processes described above.
  • This automation allows the operator to quickly and accurately measure the effect of pH on the stability of a protein in a particular buffer solution. It also allows rapid comparison of different buffer solutions, as described above.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

A system and method for creating a buffer solution having a desired pH value is disclosed. The method uses two known buffer solutions, each with predetermined pH values, and determines a mathematical relationship which defines the amount of each known buffer solution needed to create the buffer solution with the desired pH. This method can then be used to create one or more denaturation graphs, which demonstrate the stability of a protein at a given pH level.

Description

  • This application claims priority from U.S. Provisional Patent Application Ser. No. 61/375,920, filed Aug. 23, 2010, the disclosure of which are incorporated herein by reference in its entirety.
  • BACKGROUND OF THE INVENTION
  • Protein therapeutics is the fastest growing segment of the biotechnology and pharmaceutical industry. Protein therapeutics includes monoclonal antibodies, recombinant proteins, chimeric proteins and other protein receptor constructs. This segment is expected to reach over $70 billion in sales by 2011.
  • A major hurdle in the development and use of proteins as pharmaceutical drugs is the ability to store, transport and deliver them in a safe stable form. It is well known that factors, such as temperature, solvent, ligands, excipients, pH, and salt concentration, affect a particular protein's stability. The identification of buffer, ligand and excipient conditions that maximize the stability and eliminate protein aggregation is critical during development and often requires the evaluation of hundreds of conditions. This combination of buffer, ligand and excipients conditions is referred to as the storage formulation throughout this disclosure. Unfortunately, it is difficult to vary all of the various parameters to determine the ideal storage formulation for a particular protein.
  • There are different ways to measure protein stability and each involves disrupting the protein structure through either physical or chemical means. This disruption of the protein structure is referred to as denaturation.
  • Temperature is one of the most widely used physical denaturants. In this scenario, a protein is subjected to increasing temperature and the corresponding changes in its structure are recorded. One of the disadvantages of temperature denaturation is that proteins typically denature at temperatures at or above 60° C. However, in most instances, the temperatures of interest are physiological (about 37° C.), room (about 25° C.) and storage (4° C.). Thus, results from temperature-based denaturation tests must be extrapolated by more than 25° C. to understand the effects at the temperatures of interest. In addition, most proteins used as biologics undergo irreversible temperature denaturation, which precludes a meaningful calculation of thermodynamic stability at the temperatures of interest. Also, a formulation that elicits a higher denaturation temperature does not necessarily result in a more stable protein at room temperature.
  • A second way to measure protein stability is through the use of chemical denaturants, such as urea or guanidine hydrochloride. This method permits measurements to be done at any desired temperature.
  • The structural stability of a protein is determined by its Gibbs energy of stability, ΔG. This value, ΔG, is a function of temperature, chemical denaturants and other physical and chemical variables. Using the common example of a two state model, where a protein is either folded (i.e. native) or unfolded (i.e. denatured), the protein can transition between these two states:
      • N
        Figure US20120045846A1-20120223-P00001
        U, wherein N is the native (folded) state and U is the unfolded state.
  • Two different rate constants can be defined from this transitional equation. Kf is the rate of the folding reaction, while Ku is the rate of the unfolding reaction. Finally, the equilibrium constant, K, can be defined as the ratio of the unfolding rate to the folding rate, or
  • K = K u K f .
  • Furthermore, the Gibbs energy can be expressed in terms of K, as

  • ΔG=−RT ln(K),
  • where R is the gas constant, T is the temperature, expressed in Kelvin and ln(K) is the natural log of K. Thus, if K is greater than one, the protein unfolds at a higher rate than it folds, and its Gibbs energy is negative. Conversely, if K is less than one, the protein unfolds at a slower rate than it folds, and its Gibbs energy is positive. Also, K is equal to the ratio of the concentration of protein in the unfolded state and the concentration of protein in the folded state K=[U]/[F].
  • In addition, it has been observed that, for chemical denaturants, a nearly linear relationship exists between the Gibbs energy and the concentration of the denaturant. This relationship may be expressed as

  • ΔG=ΔG 0 −m*[denaturant],
  • where ΔG0 is the intrinsic Gibbs energy, [denaturant] is the concentration of denaturant, and m is the multiplier, which is unique for a particular protein.
  • For a native/unfolded equilibrium, the fraction of protein molecules which are unfolded, or denatured, Fd, is given by:
  • F d = K 1 + K ,
  • where K is the equilibrium constant.
  • This equation can be used to allow calculation of a denaturation curve. When a protein changes from its folded state to an unfolded state, certain measurable characteristics of the protein also change. One such characteristic is the fluorescence of the protein.
  • While the preferred embodiment described in this application utilizes fluorescence emission (intrinsic or extrinsic) as a way to determine the degree of denaturation or unfolding of a protein, the disclosure is not limited to this technique. There are many physical observable properties and their associated instrumentation, in addition to fluorescence spectroscopy, that are sensitive to the degree of denaturation of a protein. These observable properties include, but are not limited to uv/vis spectroscopy, circular dichroism, nuclear magnetic resonance (NMR), infrared spectroscopy (IR) among others.
  • FIG. 1 shows a typical urea denaturation curve for an antibody. The y, or vertical, axis is a measure of the intrinsic fluorescence of the protein. The fluorescence of different dyes, usually known as protein probes, can also be used. The horizontal, or x, axis is the concentration of urea in solution with the protein. As can be seen, at a certain point, between 3M and 4M urea, the fluorescence of the protein changes dramatically, indicating that it has denatured.
  • The generation of the data needed to produce such a graph is laborious. In one scenario, a solution containing the protein and any excipients is prepared. A sample of this solution is then subjected to fluorescent light and the emission is recorded. This is the baseline fluorescence with no chemical denaturant. In some embodiments, an amount of urea is then added to the remainder of the solution, and the light test is repeated on a portion of this modified solution. An additional amount of urea is then added to the remainder of the solution and a third light test is performed. This process is repeated for the number of desired samples. The amount of urea added each time is a function of the desired granularity of the test, and the range of urea molarities to be included. Such a method is prone to errors, as there are cumulative errors due to the constant addition of urea to the remaining solution. In this stepwise urea addition method, the process will result in the dilution of the protein and also a smaller fluorescence signal. In addition, since the solubility of urea is about 10.5M and a final 8M urea concentration is needed, the starting protein solution volume needs to be extremely small. The protein will be significantly diluted as the experiment progresses.
  • In another embodiment, a plurality of solutions, each with the protein, any excipients, and the proper amount of urea, is individually prepared. Each of these prepared solutions is then light tested to determine its fluorescence. While this method removes the cumulative errors associated with the previous method, it is extremely time consuming, especially for a large number of samples.
  • The resulting denaturation graph shows the stability of a particular combination of buffer, ligand and excipient conditions in the presence of a chemical denaturant. More stable combinations have a similarly shaped graph, shifted to the right. Conversely, less stable combinations have a graph shifted to the left. The goal of this testing is to find a combination with the maximum stability in the presence of the chemical denaturant. This combination can then be used as the storage formulation for the protein as it is stored and shipped.
  • Given the increased importance of developing proteins for pharmaceutical purposes, there is a dearth of systems and methods available to aid in the determination of the ideal storage formulation in which the protein is most stable.
  • For example, one important parameter that affects protein stability is pH. However, there are no known methods to create a buffer solution having a specific pH, which can then be used for denaturation testing. Furthermore, there are no automated methods that can be used to accurately achieve a plurality of buffer solutions, each having a desired pH, such as for use in a denaturation test, without the need to measure the pH for each solution.
  • SUMMARY OF THE INVENTION
  • A system and method for automatically creating a buffer solution having a desired pH value is disclosed. In accordance with certain embodiments, the method uses two known buffer solutions, each with predetermined or known pH values, and determines a mathematical relationship which defines the amount of each known buffer solution needed to create the buffer solution with the desired pH. This method can then be used to create one or more denaturation graphs, which demonstrate the stability of a protein at a given pH level.
  • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1 is a denaturation graph of the prior art;
  • FIG. 2 is a flowchart illustrating a process to generate a denaturation graph with a desired salt concentration;
  • FIG. 3 is a graph showing the relationship between Fraction Basic and pH for a particular buffer;
  • FIG. 4A is the inverse of FIG. 3;
  • FIG. 4B is a best fit fourth order equation;
  • FIG. 4C is a best fit fifth order equation;
  • FIG. 5 is a flowchart illustrating a process to determine the non-linear best fit relationship between pH and Fraction Basic for a particular buffer;
  • FIG. 6 is a flowchart illustrating a process to generate a denaturation graph with a desired pH; and
  • FIG. 7 is a flowchart illustrating a process to create a library of predetermined best fit equations for a plurality of buffers.
  • DETAILED DESCRIPTION OF THE INVENTION
  • FIG. 1 shows a typical denaturation graph, used to determine the stability of a protein in the presence of a chemical denaturant. This graph shows the stability of the protein for a particular combination of buffer, ligand and excipients conditions. However, it is often useful to view a plurality of these graphs to understand how changes in the buffer, ligand or excipients affects the stability of the protein.
  • For example, for a particular combination, it may be of interest to understand how various concentrations of a compound, such as a salt, pH, excipients, or ligands may affect the stability of the protein. For example, it may be of interest to measure the effects of different concentrations of salt in combination with a particular buffer and ligand. To do this, one may create four different formulations:
      • Formulation 1: solution with minimum salt and no denaturant
      • Formulation 2: solution with minimum salt and maximum denaturant
      • Formulation 3: solution with maximum salt and no denaturant
      • Formulation 4: solution with maximum salt and maximum denaturant
  • While the descriptions in this disclosure refer to certain formulations having no denaturant, it is understood that, in another embodiment, Formulations 1 and 3 contain a minimum amount of denaturant, which may be greater than 0, while Formulations 2 and 4 contain a maximum amount of denaturant.
  • To create a denaturation graph, one may begin by using only formulations 1 and 2. By combining these two formulations in different proportions, one can create a plurality of solutions, each with a minimum amount of salt and a varying amount of chemical denaturant. This plurality of solutions can be used to create a first denaturant graph.
  • Similarly, formulations 3 and 4 can be used to create a second denaturation graph, showing the stability of a solution with a maximum amount of salt with varying amounts of chemical denaturant.
  • A set of other graphs can also be created, each of which has a salt concentration between the minimum and maximum values. The particular number of graphs within the set is not particularly limited, and can be predetermined or arbitrary. For example, a denaturation graph showing the effect of chemical denaturant, with a salt concentration that is the average of the minimum and maximum values, may be created. In this scenario, a new formulation is created by mixing Formulation 1 and Formulation 3 in equal amounts. This new formulation has a salt concentration exactly halfway between the minimum and maximum values, with no chemical denaturant. Similarly, a second new formulation is created by mixing equal amounts of Formulation 2 and Formulation 4. This new formulation has a salt concentration exactly halfway between the minimum and maximum values, with a maximum amount of chemical denaturant. The denaturant graph for this salt concentration is then created as described above.
  • This process can be repeated a plurality of times to create the required or desired granularity of salt concentration. FIG. 2 shows a flowchart showing this sequence. In step 100, the four formulations, labeled F1 through F4, are prepared. These four formulations represent the four corners of the testing. In step 110, a fifth formulation, which has the desired amount of salt and no chemical denaturant, is prepared, using the equation shown. This equation assumes a linear relationship and is used to create any desired concentration between the minimum salt concentration and the maximum salt concentration. Similarly, in step 120, a sixth formulation, which has the desired amount of salt and the maximum amount of chemical denaturant is prepared, using the equation shown. It should be noted that the fifth and sixth concentrations may each be prepared in a separate well or vessel, so as to be available for future use. However, in other embodiments, the fifth and sixth formulations need not be independently created. Rather, the formulations F1, F2, F3 and F4 may be combined in the specific ratios described by these equations in a single well or vessel, without the intermediate formulations F5, F6 being prepared in a separate vessel. Thus, the terms “fifth formulation” and “sixth formulation” are used to express the ratios of F1 and F3, and F2 and F4, respectively, even in the scenario where such formulations may not exist in an isolated vessel. Finally, as shown in step 130, using the fifth and sixth formulations, a denaturation graph can be prepared. For an eleven point graph, the F5 and F6 formulations may be combined as shown in Table 1 below.
  • TABLE 1
    Point Number % of F5 % of F6
    1 100 0
    2 90 10
    3 80 20
    4 70 30
    5 60 40
    6 50 50
    7 40 60
    8 30 70
    9 20 80
    10 10 90
    11 0 100
  • Each of these points is prepared and then subjected to testing, where the observable property is measured. In one embodiment, this testing includes the measurement of the fluorescence emission of the protein itself (intrinsic) or a fluorescence probe that is sensitive to protein denaturation after being excited with a light of a wavelength that is absorbed by the protein or fluorescence probe. The fluorescence of each data point is measured and recorded. The fluorescence is then plotted as a function of the molarity of the chemical denaturant. The result of this process is a denaturation graph. The process shown in FIG. 2 can be repeated for an arbitrary number of salt concentrations.
  • Certain elements, such as salt, can be mixed according to linear models, using the equations shown in steps 110 and 120 of FIG. 2.
  • However, other parameters cannot be calculated linearly. One such important parameter is pH. For example, if equal parts of a base solution with a pH of 10 is mixed with an acid having a pH of 4, the resulting mixture does not necessarily have a pH of 7. Thus, the process shown in FIG. 2 to create a plurality of denaturation graphs cannot be used with consistent reliability for characterization of the effect of pH on protein stability.
  • In one embodiment, an acidic solution, having a pH of 4, is created. The solution may contain L-histidine and is made acidic through the introduction of one or more acids, such as succinic acid and/or phosphoric acid. If necessary, the pH can be increased through the introduction of NaOH. A basic solution, having a pH of 9, is also created using L-histidine. In this case, Na2HPO4 is used to make the solution basic. If necessary, the pH can be further increased through the introduction of NaOH.
  • In one embodiment, these two solutions are mixed in a plurality of combinations, and the pH of each resulting mixture is measured. FIG. 3 shows the actual measured pH for these solutions. The x, or horizontal, axis is the fraction of the resulting mixture which is the base, also referred to as Fraction Basic (FB), expressed as
  • V B V A + V B ,
  • where VB, is the volume of basic solution and VA is the volume of acidic solution. The y, or vertical, axis represents the pH of the mixture. The points on the graph represent actual measured pH values, while broken line 150 is used to show a theoretical linear relationship between x and y from the pH 4 solution to the pH 9 solution. As can be readily seen, a linear relationship, such as that used in FIG. 2, is not an accurate representation of the pH relationship. Thus, the method and equations described in conjunction with FIG. 2 will not produce accurate results.
  • It should be noted that FIG. 3 shows the pH of mixtures of two solutions. Different curves may be obtained if L-histidine is replaced with a different protein stabilizing inducing ligand.
  • Of more interest is the inverse of this graph. In other words, it would be useful to know the required Fraction Basic (FB) for a desired pH. FIG. 4A shows the graph of Fraction Basic (FB) as a function of pH. This is obtained by simply reversing the coordinates of each point on the graph shown in FIG. 3. Line 160 again is drawn to show a theoretical linear relationship between Fraction Basic (FB) and pH, from the pH 4 solution to the pH 9 solution.
  • Using the points shown on the graph of FIG. 4A, a non-linear best fit line can be drawn. In some embodiments, a best fit cubic equation is generated. For example, in the example shown in FIGS. 3 and 4A, the best fit cubic equation is given by:

  • F B=0.58−0.544*pH+0.13*pH2−0.00722*pH3
  • In another embodiment, a higher order best fit equation is generated, such as a fourth or fifth order equation. FIG. 4B shows a best fit fourth order equation, given by the formula:

  • F B=−4.796+3.034*pH−0.739*pH2+0.0845*pH3−0.00354*pH4
  • FIG. 4C shows a best fit fifth order equation, given by the formula:

  • F B=−22.28+17.658*pH−5.54*pH2+0.857*pH3−0.0646*pH4+0.001896*pH5
  • The use of a higher order best fit equation allows for an accurate relationship between pH and Fraction Basic over a wide range of pH values, such as between 3 and 9, or even wider. Thus, a non-linear mathematical relationship can be used to determine the appropriate ratios of acid and base to create a buffer of any desired pH value for a given ligand.
  • FIG. 5 represents a simplified flowchart of this operation. In step 200, the buffer is prepared in two solutions, one acidic having a first pH, and one basic, having a second, higher pH. The two pH values can be any values, such as 3 and 9, or other ranges. In step 210, a plurality of formulations is prepared, each with a unique Fraction Basic (FB). In one embodiment, formulations having twenty or more unique FB values are created. Each of these formulations is then tested to determine its pH, as shown in step 220. The results of this test are plotted, as shown in step 230. The inverse function, which shows FB as a function of pH, is then created, as shown in step 240. It should be noted that the function created in step 240 can be generated directly from the data generated in step 220. Once the points have been determined, a computer tool, or other method, may be used to determine the best non-linear best fit mathematical relationship between pH and FB for this buffer, as shown in step 250. In some embodiments, a cubic equation is generated, although other order polynomials may also be used.
  • Once this equation has been generated, the process of creating a plurality of different denaturation graphs, each with common buffer and ligand, and a different pH, can be completed. FIG. 6 shows a modified version of the flowchart of FIG. 2, which can be used to generate denaturation graphs for a plurality of pH values. Thus, this method allows the creation of a buffer of any desired pH simply by mixing two solutions of different pH values in appropriate proportions, as determined by a non-linear mathematical relationship, such as a cubic equation. It should be noted that the fifth and sixth concentrations F5, F6, respectively, can each be prepared in a separate well or vessel, so as to be available for future use. However, in other embodiments, the fifth and sixth formulations may not be independently created. Rather, the formulations F1, F2, F3 and F4 may be combined in the specific ratios described by these equations in a single well or vessel, without the intermediate formulations F5, F6 being prepared in a separate vessel. Thus, the terms “fifth formulation” and “sixth formulation” are used to express the ratios of F1 and F3, and F2 and F4, respectively, even in the scenario where such formulations may not exist in an isolated vessel. This method is ideally suited for automatic generation of buffer solutions of specified pH values
  • It is believed that buffer solution containing different ingredients will generate somewhat different mathematical relationships. Therefore, it may be necessary to perform the method described in FIGS. 3-5 for each set of ingredients to determine its best fit equation. However, once generated, these equations are applicable to denaturation testing for any protein.
  • FIG. 7 shows a method that is used to create a library of buffers, which can then be used to create a plurality of denaturation graphs for any protein. A first buffer is prepared in acid and base solutions, as shown in step 300. As described above, formulations having various Fraction Basic values are prepared, as shown in step 310. Each formulation is pH test (step 320) and based on this, the non-linear best fit mathematical relationship is determined for this particular ligand, as shown in step 340. This equation is then saved, and associated with the particular buffer, such as in a database or other computer storage medium, as shown in step 340. Finally, a different buffer is selected (step 350) and this process is repeated. This process can be performed for as many buffers as desired.
  • The generation of a table or database of buffers, and corresponding non-linear best fit equations can be used to determine the best buffer to use with a particular protein. After a particular protein has been identified as suitable for a pharmaceutical purpose, it may be advantageous to determine the pH and buffer in which the protein is most stable. The operator may select a first buffer, which has been previously characterized such that a pre-determined non-linear best fit mathematical relationship exists. The operator may then select the desired range of pH values that are desired to be tested, as well as the division or step size. Then, by repeated execution of the flowchart shown in FIG. 6, a set of denaturation graphs is generated for the selected buffer, where each graph represents a specific pH value within the range requested by the operator.
  • After this set of tests is completed, the operator may select a second buffer, which has been previously characterized such that a pre-determined non-linear best fit mathematical relationship exists. The procedure detailed above is then repeated for this second buffer. This process can be repeated for as many buffers as desired.
  • In one embodiment, the processes described herein may be automated. In this embodiment, an apparatus having a controller with a processing unit and a storage element is used. The storage element may be RAM, DRAM, ROM, Flash ROM, EEROM, magnetic media, or any other medium suitable to hold computer readable data and instructions. The instructions may be those necessary to execute the flowchart of FIG. 2, FIG. 5 or FIG. 6. The processing unit may be a dedicated microcontroller, a personal computer or any other suitable computing device. In addition, the apparatus has a pump or siphon system, which allows cannulas to extract liquid from a first well (F1), a second well (F2), a third well (F3) and a fourth well (F4) in exact quantities and mix these liquids together, preferably in another well. The apparatus also includes one or more actuators, which can move the cannulas from one position to another, so as to draw fluid from a first well and expel the fluid into a second well. In this embodiment, the operator may enter the identity of the buffer that is desired. The equipment, in its storage element, may have a mapping which correlates the selected buffer with the non-linear equation to be used. The operator then enters the pH minimum, pH maximum and pH step size. In another embodiment, the operator enters the coefficients of the non-linear best fit equation.
  • As stated above, in some embodiments, the generation of the non-linear mathematical relationship is generated automatically. To execute the flowchart of FIG. 5, the controller may be in communication with a pH indicator. This is so that after using the above described equipment to create formulations with various Fraction Basic values, the pH indicator may provide pH information to the controller, as shown in steps 230 and 240. In addition, the controller may also have a software application that creates a non-linear best fit mathematical relationship based on the Fraction Basic values and the measured pH values. Using the resulting best fit mathematical relationship, a formulation having any desired pH can be created.
  • Based on the entered parameters, the controller executed a series of instructions or steps. The coefficients of the non-linear best fit equation are selected, which allows the controller to determine Fraction Basic for a given pH. Then, the pH to be tested is determined. For the first test, this is equal to the pH minimum entered by the operator.
  • For each pH, the controller, using the flowchart of FIG. 6, creates a denaturation curve. This data can be output, such as on a display device or printer. In some embodiments, this graph is stored in the storage element of the apparatus.
  • For each subsequent test, the new pH to be tested is equal to pH min+pH step size*(test number−1). In other words, the new pH to be tested is equal to the pH that was previously tested+pH step size. Using this new pH value, a new Fraction Basic is determined, and the process of FIG. 6 is repeated. This process is repeated until the pH to be tested is greater than the pH maximum entered by the operator. At this point, the pH testing for the selected buffer has been completed.
  • The operator may then enter a different buffer to be tested and enter the required parameters to the apparatus and repeat the processes described above. This automation allows the operator to quickly and accurately measure the effect of pH on the stability of a protein in a particular buffer solution. It also allows rapid comparison of different buffer solutions, as described above.
  • The present disclosure is not to be limited in scope by the specific embodiments described herein. Indeed, other various embodiments of and modifications to the present disclosure, in addition to those described herein, will be apparent to those of ordinary skill in the art from the foregoing description and accompanying drawings. Thus, such other embodiments and modifications are intended to fall within the scope of the present disclosure. Further, although the present disclosure has been described herein in the context of a particular implementation in a particular environment for a particular purpose, those of ordinary skill in the art will recognize that its usefulness is not limited thereto and that the present disclosure may be beneficially implemented in any number of environments for any number of purposes.

Claims (19)

What is claimed is:
1. A method of preparing a buffer of a desired pH using a first solution of said buffer having a first pH and a second solution of said buffer having a second pH, comprising:
preparing a plurality of formulations, each having a different fraction of said first solution;
determining the pH of each of said formulations;
recording each of said fractions and said determined pH values;
determining a non-linear best fit mathematical relationship between said fraction and said pH;
entering desired pH value into said non-linear mathematical relationship to determine a fraction of said first solution to be used to achieve said desired pH; and
preparing said buffer of said desired pH using said determined fraction of said first solution.
2. The method of claim 1, wherein said first solution is a basic solution and said second solution is an acidic solution.
3. The method of claim 1, wherein said non-linear mathematical relationship comprises a cubic relationship.
4. The method of claim 1, wherein said non-linear mathematical relationship comprises a fourth order relationship.
5. The method of claim 1, wherein said non-linear mathematical relationship comprises a fifth order relationship.
6. A method of creating a denaturizing graph for a buffer at a desired pH, comprising:
providing a first solution with a first pH and a predetermined minimum amount of chemical denaturant; a second solution having said first pH and a predetermined maximum amount of a chemical denaturant; a third solution having a second pH and a predetermined minimum amount of chemical denaturant; and a fourth solution having said second pH and said predetermined maximum amount of said chemical denaturant;
using the method of claim 1 to combine said first solution and said third solution into a fifth solution having said desired pH and a predetermined minimum amount of chemical denaturant;
using the method of claim 1 to combine said second solution and said fourth solution into a sixth solution having said desired pH and said maximum amount of chemical denaturant;
mixing said fifth and sixth solution in a plurality of samples, each having said fifth and sixth solution in different proportions to create solutions having different molarities of said chemical denaturant;
measuring an observable property of each of said plurality of samples; and
creating a denaturation graph based on said observable property and said molarity.
7. The method of claim 6, wherein said observable property comprises fluorescence.
8. The method of claim 6, wherein said fifth solution and sixth solution are created in respective containers.
9. The method of claim 6, wherein said observable property comprises fluorescence.
10. The method of claim 6, wherein said chemical denaturant comprises urea.
11. The method of claim 6, wherein said predetermined minimum amount of denaturant comprises no denaturant.
12. An apparatus for generating a denaturation graph for a buffer at a desired pH, comprising:
a first well comprising a first solution with a first pH and a predetermined minimum amount of chemical denaturant;
a second well comprising a second solution with a first pH and a predetermined maximum amount of chemical denaturant;
a third well comprising a third solution with a second pH and a predetermined minimum amount of chemical denaturant;
a fourth well comprising a fourth solution with a second pH and a predetermined maximum amount of chemical denaturant;
a storage element, comprising a set of instructions adapted to:
use the method of claim 1 to combine said first solution and said third solution into a fifth solution having said desired pH and a predetermined minimum amount of chemical denaturant; and
use the method of claim 1 to combine said second solution and said fourth solution into a sixth solution having said desired pH and said maximum amount of chemical denaturant;
wherein said storage element further comprises said non-linear best fit mathematical relationship;
a controller adapted to execute said instructions; and
a pump or siphon system to draw said first solution from said first well, said second solution from said second well, said third solution from said third well, and said fourth solution from said fourth well in exact quantities and combine said solutions.
13. The apparatus of claim 12, wherein said non-linear best fit mathematical relationship comprises a cubic relationship.
14. The apparatus of claim 12, further comprising instructions adapted to:
mix said fifth and sixth solution in a plurality of samples, each having said fifth and sixth solution in different proportions to create solutions having different molarities of said chemical denaturant;
measure an observable property of each of said plurality of samples; and
create a denaturation graph based on said observable property and said molarity.
15. The apparatus of claim 14, further comprising a detector to determine said observable property.
16. The apparatus of claim 14, wherein said observable property comprises fluorescence.
17. The apparatus of claim 12, further comprises one or more cannulas to draw said solutions from said wells.
18. The apparatus of claim 17, further comprises an actuator to move said cannulas to each of said wells.
19. The apparatus of claim 14, wherein said chemical denaturant comprises urea.
US13/214,353 2010-08-23 2011-08-22 SYSTEM AND METHOD FOR pH FORMULATIONS Abandoned US20120045846A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/214,353 US20120045846A1 (en) 2010-08-23 2011-08-22 SYSTEM AND METHOD FOR pH FORMULATIONS
PCT/US2011/048799 WO2012027361A2 (en) 2010-08-23 2011-08-23 Automated denaturation graphs
US14/709,666 US9606061B2 (en) 2010-08-23 2015-05-12 System and method for pH formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37592010P 2010-08-23 2010-08-23
US13/214,353 US20120045846A1 (en) 2010-08-23 2011-08-22 SYSTEM AND METHOD FOR pH FORMULATIONS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/709,666 Division US9606061B2 (en) 2010-08-23 2015-05-12 System and method for pH formulations

Publications (1)

Publication Number Publication Date
US20120045846A1 true US20120045846A1 (en) 2012-02-23

Family

ID=45594239

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/214,361 Active US8609040B2 (en) 2010-08-23 2011-08-22 System for creation of formulations and generation of denaturation graphs
US13/214,353 Abandoned US20120045846A1 (en) 2010-08-23 2011-08-22 SYSTEM AND METHOD FOR pH FORMULATIONS
US13/214,357 Expired - Fee Related US9029163B2 (en) 2010-08-23 2011-08-22 Method for generation of automated denaturation graphs
US13/214,355 Active 2033-04-27 US8859295B2 (en) 2010-08-23 2011-08-22 System and method to measure dissociation constants
US14/709,666 Active US9606061B2 (en) 2010-08-23 2015-05-12 System and method for pH formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/214,361 Active US8609040B2 (en) 2010-08-23 2011-08-22 System for creation of formulations and generation of denaturation graphs

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/214,357 Expired - Fee Related US9029163B2 (en) 2010-08-23 2011-08-22 Method for generation of automated denaturation graphs
US13/214,355 Active 2033-04-27 US8859295B2 (en) 2010-08-23 2011-08-22 System and method to measure dissociation constants
US14/709,666 Active US9606061B2 (en) 2010-08-23 2015-05-12 System and method for pH formulations

Country Status (2)

Country Link
US (5) US8609040B2 (en)
WO (1) WO2012027361A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107076759A (en) * 2014-07-21 2017-08-18 非链实验室 Protein aggregation is determined from Δ G concentration dependent

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609040B2 (en) 2010-08-23 2013-12-17 Avia Biosystems, Llc System for creation of formulations and generation of denaturation graphs
SG11201606379UA (en) 2014-02-05 2016-09-29 Univ Deakin Aptamer construct
CN109738411B (en) * 2019-01-31 2019-10-11 中南民族大学 A kind of bionic array sensor and its application based on quantum dot fluorescence quenching
WO2022038521A1 (en) 2020-08-18 2022-02-24 Regenacellx.SL Compositions and methods for detecting sars-cov-2 spike protein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132916A (en) * 1990-05-21 1992-07-21 Elsag International B.V. Methodology for ph titration curve estimation for adaptive control

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306510A (en) 1988-01-14 1994-04-26 Cyberlab, Inc. Automated pipetting system
US6203759B1 (en) * 1996-05-31 2001-03-20 Packard Instrument Company Microvolume liquid handling system
US7166470B2 (en) * 1994-10-18 2007-01-23 Symyx Technologies, Inc. Formation of combinatorial arrays of materials using solution-based methodologies
CA2253587C (en) 1996-05-09 2008-01-29 3-Dimensional Pharmaceuticals, Inc. Microplate thermal shift assay and apparatus for ligand development and multi-variable protein chemistry optimization
WO1998032000A1 (en) * 1997-01-17 1998-07-23 Smithkline Beecham Corporation Apparatus and process for arraying beads
US5985214A (en) * 1997-05-16 1999-11-16 Aurora Biosciences Corporation Systems and methods for rapidly identifying useful chemicals in liquid samples
WO1999014368A2 (en) 1997-09-15 1999-03-25 Whitehead Institute For Biomedical Research Methods and apparatus for processing a sample of biomolecular analyte using a microfabricated device
US6902703B2 (en) 1999-05-03 2005-06-07 Ljl Biosystems, Inc. Integrated sample-processing system
US6063339A (en) 1998-01-09 2000-05-16 Cartesian Technologies, Inc. Method and apparatus for high-speed dot array dispensing
US6627446B1 (en) * 1998-07-02 2003-09-30 Amersham Biosciences (Sv) Corp Robotic microchannel bioanalytical instrument
US6551557B1 (en) * 1998-07-07 2003-04-22 Cartesian Technologies, Inc. Tip design and random access array for microfluidic transfer
US6132582A (en) * 1998-09-14 2000-10-17 The Perkin-Elmer Corporation Sample handling system for a multi-channel capillary electrophoresis device
US7244396B2 (en) * 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US6589791B1 (en) * 1999-05-20 2003-07-08 Cartesian Technologies, Inc. State-variable control system
US6488829B1 (en) 1999-08-05 2002-12-03 Essen Instruments Inc High-throughput electrophysiological measurement apparatus
US6734023B1 (en) * 2000-04-28 2004-05-11 Duke University Quantitative, high-throughput screening method for protein stability
US6982063B2 (en) * 2001-05-25 2006-01-03 Matrix Technologies Corp Automated pipetting system
KR20030080140A (en) * 2002-04-04 2003-10-11 엘지전자 주식회사 Method and apparatus for controlling screen of monitor
FR2884926B1 (en) 2005-04-20 2007-08-10 Bio Rad Pasteur Sa SUPPORT FOR REACTION CONTAINERS WITH PIVOTING TRAYS, ANALYSIS APPARATUS COMPRISING SUCH A SUPPORT, AND CORRESPONDING ANALYSIS METHOD.
JP4476906B2 (en) 2005-09-02 2010-06-09 富士フイルム株式会社 Dispensing device
US20090298186A1 (en) 2008-02-29 2009-12-03 Michael Brigham-Burke Method to Assess Stability of Proteins
US20100208044A1 (en) * 2009-02-19 2010-08-19 Real D Stereoscopic systems for anaglyph images
US8476081B2 (en) * 2009-09-21 2013-07-02 Janssen Pharmaceutica Nv Assay for evaluating affinity and specificity of ligand-albumin binding
US8609040B2 (en) 2010-08-23 2013-12-17 Avia Biosystems, Llc System for creation of formulations and generation of denaturation graphs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132916A (en) * 1990-05-21 1992-07-21 Elsag International B.V. Methodology for ph titration curve estimation for adaptive control

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107076759A (en) * 2014-07-21 2017-08-18 非链实验室 Protein aggregation is determined from Δ G concentration dependent

Also Published As

Publication number Publication date
US8859295B2 (en) 2014-10-14
US20120045367A1 (en) 2012-02-23
US20150241354A1 (en) 2015-08-27
US9606061B2 (en) 2017-03-28
WO2012027361A2 (en) 2012-03-01
US9029163B2 (en) 2015-05-12
WO2012027361A3 (en) 2012-06-07
US20120045849A1 (en) 2012-02-23
US8609040B2 (en) 2013-12-17
US20120045841A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
US9606061B2 (en) System and method for pH formulations
Ahlner et al. PINT: a software for integration of peak volumes and extraction of relaxation rates
Weber et al. Using high-performance quantitative NMR (HP-qNMR®) for certifying traceable and highly accurate purity values of organic reference materials with uncertainties< 0.1%
US11378573B2 (en) Calibration for multi-component assays
Török et al. Identification of the factors affecting the analytical results of food allergen ELISA methods
CN107782705B (en) Method and device for measuring oil content of rock
Tripathy et al. Suction of some polyethylene glycols commonly used for unsaturated soil testing
Morvan et al. A combinatorial approach for identification of performance EOR surfactants
CN102866256B (en) Detection method and detection reagent for hypersensitive C reactive protein
CN105074434A (en) Method and device for determining a concentration of a fluorescent substance in a medium
CN105389479A (en) Analysis method and system for analyzing a nucleic acid amplification reaction
Bergsdorf et al. A guide to run affinity screens using differential scanning fluorimetry and surface plasmon resonance assays
Altenbach et al. Analyzing CW EPR spectra of Nitroxide Labeled macromolecules
Marcondes et al. Hybrid ab-initio/experimental high temperature equations of state: Application to the NaCl pressure scale
EP3073389A1 (en) Multicomponent model parameterisation
Doyle Titration microcalorimetry
US20150088433A1 (en) Automation in gaseous sample tests
CN206020441U (en) The measurement apparatus measured using standard addition method
Isaksson et al. Extended Förster theory for determining intraprotein distances: 2. An accurate analysis of fluorescence depolarisation experiments
JP7320894B1 (en) Spectrum analysis method, analysis device and analysis program
Grappin et al. Precision of the Pro-Milk method in routine determination of protein in dairy testing laboratories
JP2010002398A (en) Analyzing device
Chambliss et al. Blood oxygen determination by gas chromatography
US20220276190A1 (en) Total organic carbon and conductivity verification and calibration using a single sample
Abdullin et al. PDSFit: PDS data analysis in the presence of orientation selectivity, g‐anisotropy, and exchange coupling

Legal Events

Date Code Title Description
AS Assignment

Owner name: AVIA BIOSYSTEMS, LLC, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BROWN, RICHARD;HUTCHINS, LORRAINE;FREIRE, ERNESTO;SIGNING DATES FROM 20131218 TO 20131226;REEL/FRAME:031930/0001

AS Assignment

Owner name: UNCHAINED LABS INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AVIA BIOSYSTEMS, LLC;REEL/FRAME:036602/0012

Effective date: 20150714

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION